Medicenna Posts Quarterly Loss of $4 Million, Warns of Funding Shortfall
Key Facts
Medicenna Therapeutics reported its fiscal second-quarter 2027 results on November 17, 2026, for the quarter ended September 30, posting a net loss of $4.0 million, or $0.04 per share. The loss in the year-earlier period was about $4.9 million, or $0.06 per share, according to the company’s statement. The figures showed a year-over-year decline in net loss alongside lower operating costs. The company said its current cash resources are insufficient to fund its planned operations over the next twelve months. It added that additional financing would be necessary, placing liquidity needs alongside quarterly results at the forefront of its announcement.
Operating costs totaled $4.1 million for the quarter, compared with $5.5 million in the year-earlier period, according to the statement. Lower research and development expenses accounted for part of the decline, totaling $3.1 million versus $4.1 million a year earlier. Medicenna attributed this mainly to reduced patient recruitment and treatment activity as the ABILITY-1 trial neared completion. It also cited lower personnel costs. These factors link part of the narrower loss to the pace of clinical development and operating spending during the period.
On liquidity, the company said available resources do not cover its operating plans for the twelve months following the November 17 announcement. It said it would need to obtain additional financing to continue those plans. Options under consideration include equity financing, strategic partnerships, licensing and other non-dilutive financing opportunities, according to its statement. The statement did not specify the amount of financing required or a timeline for completing it. Securing financing remains a direct factor in the company’s ability to carry out its announced programs and development plans.
For its clinical program, Medicenna announced that enrollment of 152 patients in the global Phase 1/2 ABILITY-1 study was complete. The study evaluates MDNA11 alone and in combination with pembrolizumab, and enrolled patients from Canada, the United States, Australia, Europe and South Korea. In data presented at the SITC 2026 conference, treatment in 20 patients with gastrointestinal cancers who were eligible for efficacy assessment recorded an objective response rate of 40%, or 8 of 20. The disease control rate was 80%, or 16 of 20, according to the company. It said the median duration of response had not reached a defined value at the data analysis, with responses ongoing.
ABILITY-1 data also showed results for two groups of patients with melanoma resistant to immune checkpoint inhibitors. The response rate was 30% among patients with secondary resistance who received MDNA11 alone, in a group of 10 patients. Among patients with primary resistance treated with MDNA11 plus pembrolizumab, the response rate was 38% in a group of 8 patients. The company published these results in November 2026 as part of its study data. Together with the gastrointestinal cancer data, the results reflect different evaluation pathways for the drug depending on cancer type and treatment-resistance pattern.
Medicenna said it plans to hold regulatory discussions on a potential development pathway that could lead to registration of MDNA11 in gastrointestinal cancers that are MSI-H or TMB-H and resistant to checkpoint inhibitors. It also intends to continue evaluating development opportunities for the drug in patients with resistant melanoma. In another program, the company said planning is underway to submit an IND application and begin a Phase 1 human study of MDNA113 in 2027. These upcoming development plans link the results of its clinical programs with the company’s need for additional financing. The announcement comes alongside its warning that available cash is insufficient to fund planned operations over the next twelve months.